B4GALNT4

Across TCGA pan-cancer cohorts, B4GALNT4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated B4GALNT4 data layer compared with 30 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher B4GALNT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALNT4 expression acts as an unfavorable survival marker.

LUSC, SKCM, and LIHC are the cancer types where B4GALNT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.218	0.676	.013	12	view →
SKCM	DFS	Median	All	0.351	0.766	.001	10	view →
LIHC	OS	Median	All	0.098	0.774	.001	9	view →
BLCA	DFS	Median	III,IV	0.124	0.575	<.001	8	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
STAD	OS	Median	III,IV	0.169	0.641	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

B4GALNT4–LUSC (OS)

Open the LUSC breakdown →